Abstract:Altered cellular metabolism is a hallmark of cancer progression, often leading to a chemical microenvironment of solid tumors (TME) that reveals significant differences from that of normal cells. Nanotherapeutics capable of detecting distinctive chemical signals within the disparate metabolic states of invasive cancer phenotypes represents a promising avenue for eliciting a favourable anti-tumor response, thereby enhancing drug efficacy and safety through microenvironment-selective cellular uptake and intracellular release. For instance, triple-negative breast cancer (TNBC), which is notoriously difficult to treat, typically features extracellular acidification and elevated intracellular glutathione (GSH) levels. By leveraging these distinctive metabolic characteristics, we have developed a surface-modified translational human serum albumin (HSA) nanocarrier, termed His-aHSA, which features anionic carboxylic acid and pH-inducible positively charged imidazole groups. This modification endows the nanocarrier with the ability to perceive the acidic TME, responding to a pH change typical for glycolytic, lactate producing tumors, which enables selective uptake into TNBC cells and spheroids. Notably, the nanocarrier His66-aHSA demonstrated a substantial increase in uptake at pH 6.5 of invasive TNBC in comparison to the pH relevant for normal tissue (pH 7.4). Furthermore, the clinically approved chemotherapeutic agent gemcitabine was conjugated via a self-immolative, redox-sensitive linker that responds to the high GSH levels typical of TNBC cancer cells and spheroids, thereby achieving a controlled and traceless intracellular drug release. It is notable that the traceless cleavable analogue (Gem-SS-His66-aHSA) exhibits a comparable IC₅₀ value of 6.1 nM, similar to that of the native drug (4.4 nM). Conversely, the non-cleavable analogue (Gem-His66-aHSA) displays an IC₅₀ that is over 10 times higher (74.6 nm).

Design of the New Closo-Dodecarborate-Containing Gemcitabine Analogue for the Albumin-Based Theranostics Composition

Radiosensitizer-based Injectable Hydrogel for Enhanced Radio-Chemotherapy of TNBC

Enzyme-sensitive gemcitabine conjugated albumin nanoparticles as a versatile theranostic nanoplatform for pancreatic cancer treatment

Poly(imidazoyl)-Albumin Nanocarrier Responding to Two Metabolic States of Glycolytic Tumors for Targeted and Traceless Drug Delivery

Engineering Molecular Self-Assembly of Theranostic Nanoprobes for Dual-Modal Imaging-Guided Precise Chemotherapy

Cyanine-Gemcitabine Conjugates as Targeted Theranostic Agents for Glioblastoma Tumor Cells

Rational Design of Albumin Theranostic Conjugates for Gold Nanoparticles Anticancer Drugs: Where the Seed Meets the Soil?

Preparation of albumin nanospheres loaded with gemcitabine and their cytotoxicity against BXPC-3 cells in vitro

Enhanced Tumor Targeting of Crgd Peptide-Conjugated Albumin Nanoparticles in the BxPC-3 Cell Line.

Striking a Balance between Carbonate/Carbamate Linkage Bond and Reduction-Sensitive Disulfide Bond-bearing Linker for Tailored Controlled Release: In Situ Covalently Albumin-Binding Gemcitabine Prodrugs Promote Bioavailability and Tumor Accumulation.

Precise engineering of Gemcitabine prodrug cocktails into single polymeric nanoparticles delivery for metastatic thyroid cancer cells

Synthesis of Gd-DTPA Carborane-Containing Compound and Its Immobilization on Iron Oxide Nanoparticles for Potential Application in Neutron Capture Therapy

Cytosine arabinoside prodrug designed to bind plasma serum albumin for drug delivery

Aptamer–Gemcitabine Conjugates with Enzymatically Cleavable Linker for Targeted Delivery and Intracellular Drug Release in Cancer Cells

Preparation of Bovine Serum Albumin Nanoparticles Loaded with Gemcitabine and the Cytotoxic Effect on Pancreatic Cancer Cells in Vitro

Synergistic antitumor efficacy of doxorubicin and gambogic acid-encapsulated albumin nanocomposites

Transformative Nanomedicine of an Amphiphilic Camptothecin Prodrug for Long Circulation and High Tumor Uptake in Cancer Therapy.

Human Serum Albumin Labelling with a New BODIPY Dye Having a Large Stokes Shift

Antitumor Gemcitabine Conjugated Micelles from Amphiphilic Comb-Like Random Copolymers

Temozolomide, Gemcitabine, and Decitabine Hybrid Nanoconjugates: From Design to Proof-of-Concept (PoC) of Synergies toward the Understanding of Drug Impact on Human Glioblastoma Cells

Cathepsin B-responsive and gadolinium-labeled branched glycopolymer-PTX conjugate-derived nanotheranostics for cancer treatment